Verition Fund Management
FDMT icon

Verition Fund Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Verition Fund Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,909
Closed -$119K – 3703
2025
Q1 		$119K Sell
36,909
-40,904
-53% -$193K ﹤0.01% 3140
2024
Q4 		$433K Buy
+77,813
New +$611K ﹤0.01% 2561
2024
Q3 		– Sell
-39,415
Closed -$827K – 3289
2024
Q2 		$827K Buy
+39,415
New +$989K ﹤0.01% 1792
2023
Q4 		– Sell
-167,137
Closed -$2.13M – 2440
2023
Q3 		$2.13M Buy
167,137
+94,428
+130% +$1.58M 0.02% 764
2023
Q2 		$1.31M Buy
+72,709
New +$1.34M 0.02% 837

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's FDMT Position: Q2 2025 in Review

Verition Fund Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 36,909 shares — an estimated $119K sold.

Verition Fund Management first reported a position in FDMT in Q2 2023 and held it in 5 quarters. The position peaked at $2.13M in Q3 2023. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • Verition Fund Management reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 36,909 4D Molecular Therapeutics shares in Q2 2025, an estimated $119K.
  • Verition Fund Management first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 5 quarters.
  • Verition Fund Management's 4D Molecular Therapeutics position peaked at $2.13M in Q3 2023.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.